Home/ Stocks/ NMRA

Neumora Therapeutics, Inc. Common Stock

NMRA XNAS

$2.47 +0.01 (+0.40%) ▲ 15-min delayed

Open

$2.51

High

$2.52

Low

$2.41

Volume

498.7K

Market Cap

$419.75M

About Neumora Therapeutics, Inc. Common Stock

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 95 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-56,755,000	$-0.35
Q2 2025	$0	$-52,731,000	$-0.33
Q1 2025	$0	$-67,992,000	$-0.42
Q3 2024	$0	$-72,547,000	$-0.45

Related Market News

No specific coverage for NMRA yet. Check out our latest market news or earnings calendar.

Get NMRA Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Neumora Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.